Maria Mitsi

Maria Mitsi

Auto-generated profile, based on publicly available information

Maria Mitsi

Ectica Technologies AG, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2017 in Nano Letters
Verified
Journal Article
Closed access
DFDaniela Ortiz Franyuti
Daniela Ortiz Franyuti
MMMaria Mitsi
Maria Mitsi
VVViola Vogel
Viola Vogel

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MUMattia Usuelli
Mattia Usuelli
TMTimmy Meyer
Timmy Meyer
RMRaffaele Mezzenga
Raffaele Mezzenga
MMMaria Mitsi
Maria Mitsi
Physical interactions between vascular endothelial growth factor (VEGF), a central player in blood endothelial cell biology, and fibronectin, a major fibrillar protein of the extracellular matrix, are important determinants of angiogenic activity in health and disease. Conditions signaling the need for new blood vessel growth, such as hypoxia and low extracellular pH, increase VEGF-fibronectin interactions. These interactions can be further fine-tuned through changes in the availability of the VEGF binding sites on fibronectin, regulated by conformational changes induced by heparin and heparan sulfate chains within the extracellular matrix. These interactions may alter VEGF bioavailability, generate gradients, or alter the way VEGF is recognized by and activates its cell-surface receptors. Here, using equilibrium and kinetic studies, we discovered that fibronectin can also interact with the extracellular domain of the VEGF receptor 2 (VEGFR2). The VEGFR2 binding sites on fibronectin show great similarity to the VEGF binding sites, as they were also exposed upon heparin-induced conformational changes in fibronectin, and the interaction was enhanced at acidic pH. Kinetic parameters and affinities for VEGF and VEGFR2 binding to fibronectin were determined by surface plasmon resonance measurements, revealing two populations of fibronectin binding sites for each molecule. Our data also suggest that a VEGF/VEGFR2/fibronectin triple complex may be formed by VEGF or VEGFR2 first binding to fibronectin and subsequently recruiting the third binding partner. The formation of such a complex may lead to the activation of distinct angiogenic signaling pathways, offering new possibilities for clinical applications that target angiogenesis.

6 March 2006 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MMMaria Mitsi
Maria Mitsi
ZHZhenning Hong
Zhenning Hong
CCCatherine E Costello
Catherine E Costello
Matthew A NugentMatthew A Nugent
Matthew A Nugent
Interactions between components of the extracellular matrix and growth factors play critical roles in regulating angiogenesis. We conducted a detailed study of the interactions between fibronectin and vascular endothelial growth factor (VEGF) and investigated how heparin modulates these interactions using a combination of in vitro binding assays and atomic force microscopy. We found that fibronectin contains at least two binding sites for VEGF (K d ~ 200 nM) whose availability is determined by pH and the conformational state of fibronectin. Interactions between immobilized fibronectin and heparin or heparan sulfate, even for very short periods of time, promote a conformational change in fibronectin to form more elongated molecules with exposed VEGF binding sites, increasing VEGF binding. After the conformational change has occurred, the presence of heparin is not necessary to sustain the effect. Chondroitin sulfate as well as chemically desulfated derivatives of heparin and heparin fragments do not exhibit the same effect. Our data suggest a mechanism for heparin/heparan sulfate in regulating angiogenesis by modulating extracellular matrix structure and growth factor activity. (Supported by: NIH RO1 HL56200, NHI PO1 HL46902 and NCRR P41 RR10888).

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
MMMaria Mitsi
Maria Mitsi
RURiccardo Urbane
Riccardo Urbane
BSBenjamin Simon
Benjamin Simon
YKYasushi Kuromi
Yasushi Kuromi
RHRyo Hasebe
Ryo Hasebe
SDSumeer Dhar
Sumeer Dhar
The use of advanced ex-vivo human organotypic cultures is rapidly growing in the field of oncology research and diagnostics, with a focus on patient-derived organoids and tumor tissue specimens cultured in artificial systems capable of replicating tumor development mechanisms. These mechanisms include metastasis, angiogenesis and formation of dysplasia. Our objective is to enhance the label-free imaging and analytical capabilities of these complex tissue samples to enable screening and diagnostics applications.SCREEN Holdings Inc., has developed a unique infrared laser-based optical coherence tomography (OCT) technology enabling non-invasive, label-free, three-dimensional (3D) imaging of tumoroids, epithelial cystic organoids, sprouting endothelial neo-vasculature and metastatic single cells. The imaging is carried out on the 3DProSeed hydrogel plates developed by Ectica Technologies, a glass-bottom 96-well plate featuring pre-casted, synthetic and optically clear hydrogels for ex-vivo tumor cultures.Here we present culture and imaging protocols with the resulting 3D tomographic reconstructions of endothelial sprouting vessels, cystic epithelial organoids of the colon and 3D invasion assays of highly metastatic glioma cells. Citation Format: Maria Mitsi, Riccardo Urbane, Benjamin Simon, Yasushi Kuromi, Ryo Hasebe, Sumeer Dhar. Optical coherence tomography for label-free real 3D imaging of ex-vivo tumor cultures [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1884.